Important information
The information on this part of the website is restricted and may not be disclosed, published or distributed, directly or indirectly, in whole or in part, in, into or from Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland, the United States or any other jurisdiction where to do so would constitute a violation of the local securities laws or regulations of such jurisdiction.

Due to legal restrictions, the information on this part of Diamyd Medical AB (publ)'s (the "Company") website is not intended or available to certain persons. We therefore ask you to read the following information and provide the following confirmation each time you wish to access this part of the website. Please note that the terms and conditions below may be changed or updated and it is therefore important that you read them each time you visit this part of the website.

The information contained in this section of the Company's website is not intended for, and may not be accessed or distributed or disseminated, directly or indirectly, in whole or in part, by or to persons residing or located in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or the United States or any other jurisdiction where such action may constitute a violation of local securities laws or regulations, and does not constitute an offer to sell, or a solicitation of an offer to buy or acquire, subscription rights, paid subscribed shares, shares or other securities of the Company ("Securities") in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or the United States or any other jurisdiction where such action may constitute a violation of local securities laws or regulations.

No Securities have been or will be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States, and no Securities may be offered, subscribed for, exercised, pledged, granted, sold, resold, delivered or transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with all applicable securities laws of any state or other jurisdiction in the United States. No offer of the Securities is being made to the public in the United States. The Securities have not been approved or disapproved by the U.S. Securities and Exchange Commission (SEC), any state securities authority or other authority in the United States. Furthermore, the Securities have not been and will not be registered under any applicable securities laws of Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where such action may be unlawful or require registration or other action, and therefore the Securities may not be offered or sold, directly or indirectly, in or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where such action may be unlawful or require registration or other action.

This information and offering are only addressed to and directed at persons in member states of the European Economic Area (the “EEA”) and the United Kingdom, who are “Qualified Investors” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (the “Prospectus Regulation”). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Qualified Investors. This information should not be acted upon or relied upon in any member state of the EEA or the United Kingdom by persons who are not Qualified Investors.

The information contained in this section of the Company’s website is only being distributed to and is only directed at (i) persons who are outside the United Kingdom; (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as “relevant persons”). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the information contained in this section of the Company’s website.

Access to the information and documents on this part of the Company's website may be illegal in certain jurisdictions, and only certain categories of persons may be permitted to access such information and documents. All persons residing outside of Sweden who wish to access the documents on this part of the website must first ensure that they are not subject to local laws or regulations prohibiting or restricting their right to access this part of the Company's website, or if their acquisition of securities requires registration or approval. Such registration or approval has not been obtained outside Sweden. The Company assumes no responsibility for any person's violation of applicable laws and regulations.

While the Company believes that the information contained in this section of the Company's website is accurate and complete as of the date of publication, and while the Company may publish new information from time to time, the Company assumes no responsibility to update or correct such information and expressly disclaims any obligation to do so.

I certify that:
1) I am resident and located outside of Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or the United States or any other jurisdiction where access tp this part of the website or such release, publication or distribution, directly or indirectly, in whole or in part, would be unlawful or would require registration or other measures besides those required under Swedish law or (ii) a Qualified Investor within the EEA or a Qualified Investor and a Relevant Person in the United Kingdom; and

2) I am resident and located (a) in Sweden or (b) outside Sweden and any jurisdiction referred to in paragraph (1) above and, in such circumstances, I am authorized to access the information and documents on this website without restriction by law and without the need for action by the Company; and

3) I am authorized to access the information contained in this section of the Company’s website without being subject to any legal restriction and without any further action required by the Company; and

4) I will not distribute or otherwise send any information contained in this section of the Company's website to any person who is a resident of any of the jurisdictions referred to in paragraph (1) above; and

5) I have read, understood and agree to comply with the restrictions set out above.

Order GAD for preclinical research

GAD PRODUCTS